onesource

Corporate Office:
Star 1, Opp IIM Bangalore, Bilekahalli,
Bannerghatta Road, Bengaluru –
560076, India
T: +91 80 6784 0738

Registered Office:
Cyber One, Unit No. 902, Sector 30A,
Plot No - 4 & 6, Vashi,
Navi Mumbai - 400703, India
T: +91 22 2789 2924

Date: October 30, 2026

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai- 400001 **Scrip Code: 544292**	**National Stock Exchange of India Limited** Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 **Symbol: ONESOURCE**

Dear Madam/Sir,

Sub: Press Release:

Please find enclosed herewith Press Release issued by the Company titled:

OneSource Receives USFDA EIR with VAI Classification,
Marking Completion of Inspection Process at its Sterile Product Division (SPD) Facility in Bengaluru

You are requested to kindly take the same on record.

For and on behalf of
OneSource Specialty Pharma Limited

Trisha A
Digitally signed by Trisha A
Date: 2026.10.30 13:27:22 +05'30'

Trisha A
Company Secretary and Compliance Officer
Membership Number: A47635

Encl. as below

onesource

Press Release
October 30, 2026

OneSource Receives USFDA EIR with VAI Classification, Marking Completion of Inspection Process at its Sterile Product Division (SPD) Facility in Bengaluru

Bengaluru, India, October 30, 2026 – OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE) today announced that it has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for its Sterile Product Division (SPD) facility in Bengaluru, with a **'Voluntary Action Indicated' (VAI)** classification. The report follows an inspection of the facility conducted from June 22 to June 30, 2026.

Commenting on the development, Neeraj Sharma, Managing Director & CEO, OneSource Specialty Pharma, said, *"We are pleased to receive the EIR with VAI classification from the USFDA for our SPD facility. This inspection outcome reflects our continued commitment to maintaining high standards of quality, regulatory compliance and operational excellence across our operations. Our SPD facility plays an integral role in our sterile manufacturing capabilities, enabling us to support the evolving needs of our global partners."*

The development adds to OneSource's regulatory track record as it continues to build a differentiated, globally competitive CDMO platform spanning four key modalities — drug-device combination, biologics, sterile injectables and soft gelatin capsules.

About OneSource Specialty Pharma Limited
OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE) is a pure-play specialty pharmaceutical CDMO. The company focuses on the development and manufacturing of complex pharmaceutical products including biologics, drug-device combinations, sterile injectables, and oral technologies (soft gelatine capsules). It has five state-of-the-art manufacturing facilities approved by global regulatory authorities and a dedicated team of over 1,600 professionals. OneSource with its development capabilities, industry leading manufacturing capacities, and strong compliance track record, has won trust of global pharmaceutical companies seeking efficient, end-to-end solutions. For more information, please visit www.onesourcecdmo.com.

For further information, please contact:

Institutional Investors	**Corporate Communication**
Anurag Bhagania CFO **Tejaswani Fotedar** +91 9004331391 Email: investor-relations@onesourcecdmo.com	**Pallavi Panchmatia:** +91 8951939181 Email: pallavi.panchmatia@onesourcecdmo.com **Abhilash Mukherjee:** +91 89044 28907 Email: abhilash.mukherjee@onesourcecdmo.com **Harsh Sheth**: +91 9870631557 Email: harsh.sheth@mslgroup.com